JP2024515830A - 母乳を出している女性における大うつ病性障害および産後うつ病の処置における使用のための神経活性ステロイド - Google Patents

母乳を出している女性における大うつ病性障害および産後うつ病の処置における使用のための神経活性ステロイド Download PDF

Info

Publication number
JP2024515830A
JP2024515830A JP2023566515A JP2023566515A JP2024515830A JP 2024515830 A JP2024515830 A JP 2024515830A JP 2023566515 A JP2023566515 A JP 2023566515A JP 2023566515 A JP2023566515 A JP 2023566515A JP 2024515830 A JP2024515830 A JP 2024515830A
Authority
JP
Japan
Prior art keywords
compound
subject
dose
administered
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515830A5 (https=
JPWO2022232494A5 (https=
Inventor
ロバート アルフォンソ ラサー，
ジェイムズ ドハーティ，
ジェフリー マーティン ジョナス，
スティーブン ジェイ ケインズ，
ハンダン グンドゥーズ－ブルース，
エイミー イー． ブロック，
ジェフリー エー． ウォールド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics LLC
Original Assignee
Sage Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics LLC filed Critical Sage Therapeutics LLC
Publication of JP2024515830A publication Critical patent/JP2024515830A/ja
Publication of JP2024515830A5 publication Critical patent/JP2024515830A5/ja
Publication of JPWO2022232494A5 publication Critical patent/JPWO2022232494A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2023566515A 2021-04-29 2022-04-29 母乳を出している女性における大うつ病性障害および産後うつ病の処置における使用のための神経活性ステロイド Pending JP2024515830A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163181807P 2021-04-29 2021-04-29
US63/181,807 2021-04-29
PCT/US2022/026908 WO2022232494A1 (en) 2021-04-29 2022-04-29 Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female

Publications (3)

Publication Number Publication Date
JP2024515830A true JP2024515830A (ja) 2024-04-10
JP2024515830A5 JP2024515830A5 (https=) 2025-05-09
JPWO2022232494A5 JPWO2022232494A5 (https=) 2025-05-09

Family

ID=81748326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566515A Pending JP2024515830A (ja) 2021-04-29 2022-04-29 母乳を出している女性における大うつ病性障害および産後うつ病の処置における使用のための神経活性ステロイド

Country Status (9)

Country Link
US (1) US20240216396A1 (https=)
EP (1) EP4329769A1 (https=)
JP (1) JP2024515830A (https=)
CN (1) CN117580580A (https=)
AU (1) AU2022267304A1 (https=)
CA (1) CA3217866A1 (https=)
IL (1) IL307980A (https=)
MX (1) MX2023012728A (https=)
WO (1) WO2022232494A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
JP2020533310A (ja) * 2017-09-07 2020-11-19 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイドおよびそれらの使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
CN113939298A (zh) * 2018-12-14 2022-01-14 普拉西斯精密医药公司 用于治疗抑郁症的方法
US20230285417A1 (en) 2020-07-20 2023-09-14 Sage Therapeutics, Inc. Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020533310A (ja) * 2017-09-07 2020-11-19 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイドおよびそれらの使用方法
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BREASTFEEDING MEDICINE, vol. 10, no. 6, JPN6026009222, 2015, pages 290 - 299, ISSN: 0005811306 *
DRUGS OF TODAY, vol. 55, no. 9, JPN6026009223, 2019, pages 537 - 544, ISSN: 0005811307 *
EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 29, JPN6026009220, 2019, pages 6 - 219, ISSN: 0005811304 *
EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 40, JPN6026009219, 2020, pages 1 - 177, ISSN: 0005811303 *
杉本充弘編著, 「妊婦・授乳婦の薬 改訂第２版」, JPN6026009221, 2018, pages 1 - 4, ISSN: 0005811305 *

Also Published As

Publication number Publication date
IL307980A (en) 2023-12-01
WO2022232494A1 (en) 2022-11-03
MX2023012728A (es) 2023-11-08
AU2022267304A1 (en) 2023-11-02
CN117580580A (zh) 2024-02-20
EP4329769A1 (en) 2024-03-06
CA3217866A1 (en) 2022-11-03
US20240216396A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
JP2024515830A (ja) 母乳を出している女性における大うつ病性障害および産後うつ病の処置における使用のための神経活性ステロイド
Manber et al. The effects of hormone replacement therapy on sleep-disordered breathing in postmenopausal women: a pilot study
Hachul et al. Effects of hormone therapy with estrogen and/or progesterone on sleep pattern in postmenopausal women
KR20230158033A (ko) 주요 우울 장애의 치료를 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
US20240216395A1 (en) 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
KR20240148425A (ko) Cns-관련 장애의 치료를 위한 신경활성 스테로이드
WO2019094724A1 (en) Ganaxolone for use in treating genetic epileptic disoders
Boulet et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma
Silverman et al. Outcome of pregnancy in a randomized controlled study of patients with asthma exposed to budesonide
KR20220112803A (ko) 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
JP2020534270A (ja) １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
JP2008500340A (ja) 月経前不機嫌性障害の処置のための組成物および方法
JP2023539567A (ja) 神経活性ステロイドを含有する医薬組成物及びその使用
JP2019507786A (ja) 慢性閉塞性肺疾患の急性増悪の治療のための投与レジメン
Aronson Meyler's side effects of endocrine and metabolic drugs
CN117580581A (zh) 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇
CN117098554A (zh) 用于治疗重度抑郁障碍的19-去甲c3,3-二取代c21-n-吡唑基类固醇
EP3384914A1 (en) Selective progesterone receptor modulators (sprm) and stabilized estrogen level in patient
WO2025122747A1 (en) Treatment of moderate-to-severe asthma by administering rilzabrutinib
Moeindarbary et al. Guillain-Barre Syndrome following Cushing's Syndrome in a Pregnant Woman: A Case Report
WO2007143486A2 (en) Treatment of hot flashes using muscarinic receptor antagonists such as oxybutynin
Ceylan et al. Approach to Premenstrual Syndrome and Premenstrual Dysphoric Disorder from the Perspective of Family Medicine
TW202535357A (zh) 治療更年期及近更年期之方法
Brown Pharmacological management of gestational asthma
Petkova et al. Fluticasone Furoate/Vilanterol–a novel inhaled combination for once-daily use for the treatment of asthma and COPD

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260306